Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

109.64 +0.66 (+0.61%)
Streaming Delayed Price Updated: 2:33 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
7 Healthcare Stocks That Are Poised to Become the Next Unicorns
Discover healthcare stocks with remarkable potential for growth and "unicorn" status in the ever-evolving world of healthcare investments. 
Via InvestorPlace
Jazz Pharmaceuticals: Q3 Earnings Insights
Via Benzinga
Cannabis Cash Burn Concerns? Sell These 7 Overbought Stocks Now.
These overbought cannabis stocks are teetring on the edge as the sector is navigating through uncharted waters. 
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
FDA Report On Its 50 Years In Cannabis Research, Signals A Boost In Medical Marijuana Prospects
Researchers with the Food and Drug Administration (FDA) reported Wednesday on the agency’s 50 years of experience with marijuana research. In an article titled “FDA’s 50 
Via Benzinga
Topics Cannabis
Exposures Cannabis Product Safety
Ireland Reimburses Medical Marijuana-Based Drug For Chemotherapy-Induced Nausea And Vomiting
Althea Group Holdings Limited (ASX: AGH), an Australian manufacturer of cannabis-based medicines and recreational cannabis products confirmed that Ireland’s Primary Care Reimbursement... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Where Jazz Pharmaceuticals Stands With Analysts
Via Benzinga
Expert Ratings for Jazz Pharmaceuticals
Via Benzinga
Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END 
Via FinancialNewsMedia
Europe's High: UK Parents Need NHS Help For Daughter's Seizures, THC MMJ Flowers In Switzerland & More
Luxembourg: Medical Marijuana Shortage Due To Supplier Change 
Via Benzinga
Topics Cannabis Supply Chain
Exposures Cannabis Supply Chain
Cannabis Stocks Dip: How Rising Interest Rates Impact Your Portfolio
On Friday, cannabis stocks traded lower with the overall market. Marketfy analyst Michael Berger will be monitoring how the sector performs this week. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Europe's High: Irish GPs Against Pot, Switzerland-Spain Share Data On Cannabis Clubs & More
Denmark: Medical Marijuana Pilot Program Experience 90% Growth In 12 Months 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Jazz Pharmaceuticals Explores Asset Sale Option, Possibly Cannabinoid Business: Report
Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) is reportedly exploring strategic options comprising a potential sale. 
Via Benzinga
2 Top Biotech Stocks to Buy in October
Growth catalysts lie ahead for both of these players. 
Via The Motley Fool
5 Genius Safe Stocks to Buy for the 4th Quarter of 2023
These highly profitable, time-tested companies can deliver for their shareholders in any economic climate. 
Via The Motley Fool
4 Perfect Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
An 18% decline in the Nasdaq Composite from its all-time high means bargains still abound. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023
Via Benzinga
3 Cannabis Stocks That Should Be on Every Investor’s Radar This Fall
The cannabis industry is a quiet place where huge upside potential is building up. As more regions legalize, cannabis stocks can soar. 
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 22, 2023 – USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal,... 
Via FinancialNewsMedia
3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall
Even with higher for longer interest rates, drug discovery moves on. That’s why it’s still a good time to look for biotech stocks to buy. 
Via InvestorPlace
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
Via Investor Brand Network
Exposures Product Safety
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
7 Cannabis Stocks to Buy BEFORE the Marijuana Rescheduling Boom
Cannabis stocks re seeing renewed interest and these seven look like reasonable buys as rescheduling approaches for weed. 
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
Cannabis Industry Changes As Marijuana Rescheduling Looms
As the Benzinga Cannabis Capital Conference returns to Chicago this Sept 27-28 for its 17th edition, gathering top CEOs, investors and leaders in the cannabis industry, let's scroll through the top... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035. 
Via Benzinga
Prediction: These Could Be the Best-Performing Cannabis Stocks Through 2030
These two businesses may be sound, but generating returns in this industry has been tough, with no light at the end of the tunnel. 
Via The Motley Fool
Topics Cannabis
Exposures Cannabis
Epidiolex Counterpart Debuts In Brazil's Cannabis Market As Its Maker Eyes TSX IPO
Verdemed, a pharmaceutical company known for producing cannabis-derived products, has received five fresh approvals from the Brazilian Health Regulatory Agency (Agência Nacional de Vigilância... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Jazz Pharmaceuticals' Neuroscience Pipeline Readouts In Focus: Analyst Lowers Price Target
Cantor Fitzgerald analyst Charles C. 
Via Benzinga
Cannabis Stock Gainers And Losers From August 11, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Jazz Pharmaceuticals Reports Q2 2023 Net Income Of $104.4M, What About Total Revenues?
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced its financial results for the second quarter of 2023, along with its outlook for the remainder of the year. 
Via Benzinga
3 Biotech Stocks You’ll Regret Not Buying Soon
These top biotech stocks are must-buys with huge potential, leading the industry with high-rewards for investors. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS